,drugId,displayName,indication,company,country,probabilityOfSuccess,phase,startDate,endDate,successPercentage
0,72133,nogapendekin alfa,Bladder cancer,ImmunityBio Inc,US,95%,Phase 2,25-Jul-2014,02-Jun-2017,
1,72133,nogapendekin alfa,Bladder cancer,ImmunityBio Inc,US,95%,Phase 3,02-Jun-2017,11-May-2023,
2,72133,nogapendekin alfa,Bladder cancer,ImmunityBio Inc,US,95%,Pre-Reg,11-May-2023,09-Apr-2024,95%
3,72133,nogapendekin alfa,Bladder cancer,ImmunityBio Inc,US,95%,Reg,09-Apr-2024,,
7,90272,"immunoglobulin + hyaluronidase (immune deficiency/demyelinating polyneuropathy/multifocal motor neuropathy/chronic fatigue syndrome, Enhanze), Shire/Halozyme",Chronic inflammatory demyelinating polyneuropathy,Takeda Pharmaceutical Co Ltd,US,95%,Phase 3,15-Oct-2015,28-Feb-2023,
8,90272,"immunoglobulin + hyaluronidase (immune deficiency/demyelinating polyneuropathy/multifocal motor neuropathy/chronic fatigue syndrome, Enhanze), Shire/Halozyme",Chronic inflammatory demyelinating polyneuropathy,Takeda Pharmaceutical Co Ltd,US,95%,Pre-Reg,28-Feb-2023,24-Jan-2024,95%
9,90272,"immunoglobulin + hyaluronidase (immune deficiency/demyelinating polyneuropathy/multifocal motor neuropathy/chronic fatigue syndrome, Enhanze), Shire/Halozyme",Chronic inflammatory demyelinating polyneuropathy,Takeda Pharmaceutical Co Ltd,US,95%,Reg,24-Jan-2024,,
